Larimar Therapeutics Inc (NASDAQ:LRMR) has a beta value of 1.00 and has seen 0.25 million shares traded in the recent trading session. The company, currently valued at $129.01M, closed the recent trade at $2.02 per share which meant it gained $0.11 on the day or 5.50% during that session. The LRMR stock price is -454.46% off its 52-week high price of $11.20 and 20.3% above the 52-week low of $1.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.81 million shares traded. The 3-month trading volume is 753.15K shares.
The consensus among analysts is that Larimar Therapeutics Inc (LRMR) is Buy stock at the moment, with a recommendation rating of 1.08. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.41.
Larimar Therapeutics Inc (NASDAQ:LRMR) trade information
Sporting 5.50% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LRMR stock price touched $2.02 or saw a fall of -2.54%. Year-to-date, Larimar Therapeutics Inc shares have moved -47.93%, while the 5-day performance has seen it change 11.33%. Over the past 30 days, the shares of Larimar Therapeutics Inc (NASDAQ:LRMR) have changed -19.72%. Short interest in the company has seen 4.82 million shares shorted with days to cover at 5.45.
Wall Street analysts have a consensus price target for the stock at $14.5, which means that the shares’ value could jump 86.07% from the levels at last check today.. The projected low price target is $14.0 while the price target rests at a high of $15.0. In that case, then, we find that the latest price level in today’s session is -642.57% off the targeted high while a plunge would see the stock gain -593.07% from the levels at last check today..
Larimar Therapeutics Inc (LRMR) estimates and forecasts
The company’s shares have lost -73.87% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 50.78% over the past 5 years. Earnings growth for 2025 is a modest -38.94% while over the next 5 years, the company’s earnings are expected to decrease by -7.48%.
LRMR Dividends
Larimar Therapeutics Inc is expected to release its next earnings report on 2025-Mar-23 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Larimar Therapeutics Inc (NASDAQ:LRMR)’s Major holders
Insiders own 1.43% of the company shares, while shares held by institutions stand at 110.80% with a share float percentage of 112.40%. Investors are also buoyed by the number of investors in a company, with Larimar Therapeutics Inc having a total of 152.0 institutions that hold shares in the company. The top two institutional holders are DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with over 21.23 million shares worth more than $153.93 million. As of 2024-06-30, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) held 33.278% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 6.05 million shares as of 2024-06-30. The firm’s total holdings are worth over $43.83 million and represent 9.4752% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.04% shares in the company for having 1.31 shares of worth $2.65 million while later fund manager owns 1.12 shares of worth $2.27 million as of Mar 31, 2025 , which makes it owner of about 1.74% of company’s outstanding stock.
